1 active not recruiting, 1 completed, 1 enrolling by invitation. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Enrolling by invitation 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Myotonia: new trials by email Literature Review of Myotonia trials Research Report on Myotonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I VX-670 - Myotonic Dystrophy Type 1 (DM1) | Phase 2 | Enrolling by invitation | Vertex Pharmaceuticals Incorporated | 44 | 2025-04-28 | 2026-10-14 |
| A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) VX-670, Placebo - Myotonic Dystrophy Type 1 (DM1) | Phase 1 / Phase 2 | Active not recruiting | Vertex Pharmaceuticals Incorporated | 47 | 2024-02-20 | 2026-08-20 |
| Effectiveness of Mexiletine for Treating People With Non-Dystrophic Myotonia Mexiletine, Placebo - Myotonia, Non-Dystrophic Myotonia | Phase 2 | Completed | Richard Barohn, MD | 59 | 2008-12-01 | 2013-08-23 |
Genetic Diseases, Inborn (2) · Heredodegenerative Disorders, Nervous System (2) · Muscular Diseases (2) · Muscular Disorders, Atrophic (2) · Muscular Dystrophies (2) · Musculoskeletal Diseases (2) · Myotonic Disorders (2) · Myotonic Dystrophy (2) · Nervous System Diseases (2) · Neurodegenerative Diseases (2) · Neuromuscular Diseases (2)
Neurologic Manifestations (3) · Neuromuscular Manifestations (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Nervous System Diseases (1)
Mexiletine (1)
Vertex Pharmaceuticals Incorporated (2) · Richard Barohn, MD (1)
Canada (3) · United Kingdom (3) · United States (3) · Australia (2) · Belgium (2) · Germany (2) · Italy (2) · Netherlands (2) · Spain (2) · France (1)
2023 (1)